These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 29697308)
1. Emerging therapeutic targets in the short QT syndrome. Hancox JC; Whittaker DG; Du C; Stuart AG; Zhang H Expert Opin Ther Targets; 2018 May; 22(5):439-451. PubMed ID: 29697308 [TBL] [Abstract][Full Text] [Related]
2. Disopyramide is an effective inhibitor of mutant HERG K+ channels involved in variant 1 short QT syndrome. McPate MJ; Duncan RS; Witchel HJ; Hancox JC J Mol Cell Cardiol; 2006 Sep; 41(3):563-6. PubMed ID: 16842817 [TBL] [Abstract][Full Text] [Related]
3. Pro-arrhythmic effects of gain-of-function potassium channel mutations in the short QT syndrome. Hancox JC; Du CY; Butler A; Zhang Y; Dempsey CE; Harmer SC; Zhang H Philos Trans R Soc Lond B Biol Sci; 2023 Jun; 378(1879):20220165. PubMed ID: 37122211 [TBL] [Abstract][Full Text] [Related]
5. Pharmacology of the short QT syndrome N588K-hERG K+ channel mutation: differential impact on selected class I and class III antiarrhythmic drugs. McPate MJ; Duncan RS; Hancox JC; Witchel HJ Br J Pharmacol; 2008 Nov; 155(6):957-66. PubMed ID: 18724381 [TBL] [Abstract][Full Text] [Related]
6. Theoretical possibilities for the development of novel antiarrhythmic drugs. Varró A; Biliczki P; Iost N; Virág L; Hála O; Kovács P; Mátyus P; Papp JG Curr Med Chem; 2004 Jan; 11(1):1-11. PubMed ID: 14754422 [TBL] [Abstract][Full Text] [Related]
7. Reduction of dispersion of repolarization and prolongation of postrepolarization refractoriness explain the antiarrhythmic effects of quinidine in a model of short QT syndrome. Milberg P; Tegelkamp R; Osada N; Schimpf R; Wolpert C; Breithardt G; Borggrefe M; Eckardt L J Cardiovasc Electrophysiol; 2007 Jun; 18(6):658-64. PubMed ID: 17521304 [TBL] [Abstract][Full Text] [Related]
8. Cellular basis for arrhythmogenesis in an experimental model of the SQT1 form of the short QT syndrome. Patel C; Antzelevitch C Heart Rhythm; 2008 Apr; 5(4):585-90. PubMed ID: 18362027 [TBL] [Abstract][Full Text] [Related]
9. Action potential clamp and pharmacology of the variant 1 Short QT Syndrome T618I hERG K⁺ channel. El Harchi A; Melgari D; Zhang YH; Zhang H; Hancox JC PLoS One; 2012; 7(12):e52451. PubMed ID: 23300672 [TBL] [Abstract][Full Text] [Related]
10. Clinical and molecular genetics of the short QT syndrome. Schimpf R; Borggrefe M; Wolpert C Curr Opin Cardiol; 2008 May; 23(3):192-8. PubMed ID: 18382206 [TBL] [Abstract][Full Text] [Related]
11. Cardiac ion channels and mechanisms for protection against atrial fibrillation. Grunnet M; Bentzen BH; Sørensen US; Diness JG Rev Physiol Biochem Pharmacol; 2012; 162():1-58. PubMed ID: 21987061 [TBL] [Abstract][Full Text] [Related]
12. Blockers of the slowly delayed rectifier potassium IKs channel: potential antiarrhythmic agents. Gerlach U Curr Med Chem Cardiovasc Hematol Agents; 2003 Oct; 1(3):243-52. PubMed ID: 15326915 [TBL] [Abstract][Full Text] [Related]
13. Transgenic short-QT syndrome 1 rabbits mimic the human disease phenotype with QT/action potential duration shortening in the atria and ventricles and increased ventricular tachycardia/ventricular fibrillation inducibility. Odening KE; Bodi I; Franke G; Rieke R; Ryan de Medeiros A; Perez-Feliz S; Fürniss H; Mettke L; Michaelides K; Lang CN; Steinfurt J; Pantulu ND; Ziupa D; Menza M; Zehender M; Bugger H; Peyronnet R; Behrends JC; Doleschall Z; Zur Hausen A; Bode C; Jolivet G; Brunner M Eur Heart J; 2019 Mar; 40(10):842-853. PubMed ID: 30496390 [TBL] [Abstract][Full Text] [Related]
14. In silico assessment of the effects of quinidine, disopyramide and E-4031 on short QT syndrome variant 1 in the human ventricles. Luo C; Wang K; Zhang H PLoS One; 2017; 12(6):e0179515. PubMed ID: 28632743 [TBL] [Abstract][Full Text] [Related]
15. The cardiac hERG/IKr potassium channel as pharmacological target: structure, function, regulation, and clinical applications. Thomas D; Karle CA; Kiehn J Curr Pharm Des; 2006; 12(18):2271-83. PubMed ID: 16787254 [TBL] [Abstract][Full Text] [Related]
16. The hERG channel activator, RPR260243, enhances protective Shi YP; Pang Z; Venkateshappa R; Gunawan M; Kemp J; Truong E; Chang C; Lin E; Shafaattalab S; Faizi S; Rayani K; Tibbits GF; Claydon VE; Claydon TW Am J Physiol Heart Circ Physiol; 2020 Aug; 319(2):H251-H261. PubMed ID: 32559136 [TBL] [Abstract][Full Text] [Related]
17. Genotype-dependent differences in age of manifestation and arrhythmia complications in short QT syndrome. Harrell DT; Ashihara T; Ishikawa T; Tominaga I; Mazzanti A; Takahashi K; Oginosawa Y; Abe H; Maemura K; Sumitomo N; Uno K; Takano M; Priori SG; Makita N Int J Cardiol; 2015; 190():393-402. PubMed ID: 25974115 [TBL] [Abstract][Full Text] [Related]